AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7044913 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of healed ulcers
Number of subjects: 50
Study 30652973 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoquercetin 1000 mg daily for 56 days
Number of subjects: 57
Study 30652973 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoquercetin 500 mg daily for 56 days
Number of subjects: 57
Study 28912129 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory high-intensity interval training (L-HIIT)
Number of subjects: 18
Study 28912129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home high-intensity interval training (H-HIIT)
Number of subjects: 18
Study 28912129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home isometric hand-grip training (H-IHGT)
Number of subjects: 18
Study 26999644 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hydrocortisone dose (0.4-0.6 mg/kg body weight)
Number of subjects: 47
Study 26999644 — intervention group
Group type: COMPARATOR
Intervention: Lower hydrocortisone dose (0.2-0.3 mg/kg body weight)
Number of subjects: 47
Study 24219409 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 30
Study 24219409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH)
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL)
Number of subjects: 87
Study 21810288 — intervention group
Group type: COMPARATOR
Intervention: Minimal beta-glucan (control)
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH) in responders
Number of subjects: 87
Study 21810288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL) in responders
Number of subjects: 87
Study 21810288 — intervention group
Group type: COMPARATOR
Intervention: Minimal beta-glucan (control) in responders
Number of subjects: 87
Study 19446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg
Number of subjects: 13
Study 19446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 13
Study 19446153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg and Exenatide 5 microg
Number of subjects: 13
Study 17581195 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of IL-5 (10 microg via nebulizer)
Number of subjects: 19
Study 17581195 — intervention group
Group type: COMPARATOR
Intervention: Placebo (via nebulizer)
Number of subjects: 19
Study 17242322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific ratings
Number of subjects: 292
Study 17242322 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidelines
Number of subjects: 292
Study 15363825 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 103793
Study 15363825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine CCBs
Number of subjects: 103793
Study 15363825 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dihydropyridine CCBs
Number of subjects: 103793
Study 15363825 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive drugs
Number of subjects: 103793
Study 10708818 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 70
Study 10708818 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 70
Study 10708818 — intervention group
Group type: COMPARATOR
Intervention: Control group (mianserin alone)
Number of subjects: 70
Study 9387298 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP test and ultrasound every 6 months)
Number of subjects: 17920
Study 9387298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 17920
Study 1290631 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination screening (first round)
Number of subjects: 1494
Study 1290631 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination screening (second round)
Number of subjects: 1494
Study 1290631 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 1494
Study 1290631 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1494
Study 1290631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of screening
Number of subjects: 1494
Study 6147451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low food intake group
Number of subjects: 0
Study 6147451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement group
Number of subjects: 0
Study 6147451 — intervention group
Group type: COMPARATOR
Intervention: Customarily low food intake
Number of subjects: 0
Study 30538082 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic pomegranate juice (SPJ)
Number of subjects: 92
Study 30538082 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic beverage (SB)
Number of subjects: 92
Study 30538082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 92
Study 30538082 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (Control)
Number of subjects: 92
Study 29851998 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobics (45 min, twice a week for 12 weeks)
Number of subjects: 23
Study 29851998 — intervention group
Group type: COMPARATOR
Intervention: Control (no physical exercise)
Number of subjects: 23
Study 27788854 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoepicardial scar homogenization
Number of subjects: 93
Study 27788854 — intervention group
Group type: COMPARATOR
Intervention: Standard limited-substrate ablation
Number of subjects: 93
Study 24002626 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter + Personal Call
Number of subjects: 1008
Study 24002626 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter + Autodial + Prompt
Number of subjects: 1008
Study 24002626 — intervention group
Group type: COMPARATOR
Intervention: Letter + Autodial
Number of subjects: 1008
Study 24002626 — intervention group
Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 1008
Study 22516444 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary 18F‐NaF uptake in patients with coronary atherosclerosis (n = 106)
Number of subjects: 119
Study 22516444 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (calcium score = 0)
Number of subjects: 119
Study 22516444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increased coronary 18F‐NaF activity (n = 40)
Number of subjects: 119
Study 22516444 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary 18F‐FDG uptake
Number of subjects: 119
Study 20142177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 40
Study 20142177 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 40
Study 17451776 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation masking in an alignment discrimination task
Number of subjects: 0
Study 17451776 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking a Vernier stimulus
Number of subjects: 0
Study 17451776 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation masking on perceived orientation and alignment of a Vernier stimulus
Number of subjects: 0
Study 17451776 — intervention group
Group type: COMPARATOR
Intervention: Control of task-dependent effects
Number of subjects: 0
Study 15003432 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 68
Study 15003432 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 68
Study 15003432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual partner availability
Number of subjects: 68
Study 15003432 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment remission
Number of subjects: 68
Study 12240499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage on the arm 3 times a week for 4 weeks
Number of subjects: 29
Study 12240499 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 9695995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Number of subjects: 96
Study 9695995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin plus interferon alfa n‐3 for 6 months at the above doses
Number of subjects: 96
Study 9695995 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Number of subjects: 96
Study 7911406 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 46
Study 7911406 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 46
Study 7911406 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosine and Buflomedil combination
Number of subjects: 46
Study 2734402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 50
Study 2734402 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 50
Study 31485457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin (VLDM)
Number of subjects: 0
Study 31485457 — intervention group
Group type: COMPARATOR
Intervention: High-dose metformin (HDM)
Number of subjects: 0
Study 29096181 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive typing intervention (two online games played at home for four weeks)
Number of subjects: 78
Study 29096181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online games)
Number of subjects: 78
Study 29096181 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive typing intervention
Number of subjects: 78
Study 29096181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 26735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drains in the subcutaneous tissue
Number of subjects: 42
Study 26735057 — intervention group
Group type: COMPARATOR
Intervention: Progressive tension sutures
Number of subjects: 42
Study 24965545 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGB (single anastomosis gastric bypass)
Number of subjects: 60
Study 24965545 — intervention group
Group type: COMPARATOR
Intervention: SG (sleeve gastrectomy)
Number of subjects: 60
Study 24965545 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGB
Number of subjects: 60
Study 24965545 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 60
Study 22156332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22156332 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose pregabalin (150 mg before surgery)
Number of subjects: 48
Study 22156332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose pregabalin (150 mg presurgery and at 12 and 24 hours)
Number of subjects: 48
Study 19775469 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention sent monthly for 12 months
Number of subjects: 0
Study 19775469 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17521300 — intervention group
Group type: EXPERIMENTAL
Intervention: artemisinin
Number of subjects: 75
Study 17521300 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether
Number of subjects: 75
Study 17521300 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin
Number of subjects: 75
Study 17521300 — intervention group
Group type: EXPERIMENTAL
Intervention: arteether
Number of subjects: 75
Study 15363813 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time graded-release diltiazem (GRD) 360 mg
Number of subjects: 262
Study 15363813 — intervention group
Group type: COMPARATOR
Intervention: Morning amlodipine 5 mg
Number of subjects: 262
Study 12972704 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic chemotherapy
Number of subjects: 0
Study 12972704 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 0
Study 12972704 — intervention group
Group type: COMPARATOR
Intervention: Pelvic lymphadenectomy
Number of subjects: 0
Study 12972704 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy or combined radiochemotherapy
Number of subjects: 0
Study 10604299 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carteolol hydrochloride 1.0%
Number of subjects: 100
Study 10604299 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol maleate 0.5%
Number of subjects: 100
Study 7577850 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg daily for 8 weeks, then 400 mg for 16 weeks)
Number of subjects: 164
Study 7577850 — intervention group
Group type: COMPARATOR
Intervention: Gestrinone (2.5 mg twice a week for 24 weeks)
Number of subjects: 164
Study 7577850 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 164
Study 7577850 — intervention group
Group type: COMPARATOR
Intervention: Gestrinone
Number of subjects: 164
Study 2036187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (single intravenous dose)
Number of subjects: 25
Study 2036187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 2036187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 25
Study 7033744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 48
Study 7033744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 31250761 — intervention group
Group type: EXPERIMENTAL
Intervention: Viola odorata L. oil (20 drops) applied to the peripheral margin of the umbilicus
Number of subjects: 41
Study 31250761 — intervention group
Group type: EXPERIMENTAL
Intervention: Viola odorata L. oil
Number of subjects: 41
Study 31250761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 30552064 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3
Number of subjects: 360
Study 30552064 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3
Number of subjects: 360
Study 30552064 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3
Number of subjects: 360
Study 30552064 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood
Number of subjects: 360
Study 28253584 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 61
Study 28253584 — intervention group
Group type: COMPARATOR
Intervention: Passive Restraint (PR)
Number of subjects: 61
Study 25377359 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ARA-C (SDAC)
Number of subjects: 130
Study 25377359 — intervention group
Group type: COMPARATOR
Intervention: High-dose ARA-C (HDAC)
Number of subjects: 130
Study 25377359 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAC-MRD(-)
Number of subjects: 130
Study 25377359 — intervention group
Group type: COMPARATOR
Intervention: HDAC-MRD(-)
Number of subjects: 130
Study 25377359 — intervention group
Group type: EXPERIMENTAL
Intervention: SDAC-MRD(+)
Number of subjects: 130
Study 25377359 — intervention group
Group type: COMPARATOR
Intervention: HDAC-MRD(+)
Number of subjects: 130
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 4 (complete regression)
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 2 and 3 (intermediate regression)
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 0 and 1 (poor regression)
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual lymph node metastasis (ypN+)
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor regression grading (TRG)
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: ypN status
Number of subjects: 386
Study 24752056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic invasion
Number of subjects: 386
Study 22802737 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention in urban slum women's groups
Number of subjects: 18197
Study 22802737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18197
Study 22802737 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention
Number of subjects: 18197
Study 19900993 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (2000 mg)
Number of subjects: 102
Study 19900993 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus repaglinide (6 mg)
Number of subjects: 102
Study 17893258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic euglycaemic clamp (HEC)
Number of subjects: 8
Study 17893258 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II type 1 receptor blockade (losartan 200 mg) during hyperinsulinaemic euglycaemic clamp (AT-HEC)
Number of subjects: 8
Study 15573713 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 0
Study 15573713 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir (NFV)
Number of subjects: 0
Study 12477172 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hearing aids
Number of subjects: 29
Study 12477172 — intervention group
Group type: COMPARATOR
Intervention: One hearing aid
Number of subjects: 29
Study 9454552 — intervention group
Group type: EXPERIMENTAL
Intervention: Side‐to‐end anastomosis
Number of subjects: 67
Study 9454552 — intervention group
Group type: EXPERIMENTAL
Intervention: Double stapling anastomosis
Number of subjects: 67
Study 9454552 — intervention group
Group type: COMPARATOR
Intervention: End‐to‐end anastomosis
Number of subjects: 67
Study 8284649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefcanel daloxate
Number of subjects: 400
Study 8284649 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 400
Study 3424076 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (41 patients)
Number of subjects: 120
Study 3424076 — intervention group
Group type: COMPARATOR
Intervention: Surgery and radiotherapy (47 patients)
Number of subjects: 120
Study 3424076 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy (19 patients)
Number of subjects: 120
Study 3424076 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral microlaryngoscopic laser resection and postoperative irradiation
Number of subjects: 120
Study 3424076 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 120
Study 31409383 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Resistance Training (CRT)
Number of subjects: 11
Study 31409383 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 11
Study 31409383 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 11
Study 31409383 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - seated rest
Number of subjects: 11
Study 27603954 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCS100 (3 g day-1)
Number of subjects: 50
Study 27603954 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate placebo (3 g day-1)
Number of subjects: 50
Study 27603954 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCS100
Number of subjects: 50
Study 24420638 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session reality therapy drug treatment program
Number of subjects: 40
Study 24420638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 24620447 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (OM 40/AML 10/HCTZ 25 mg)
Number of subjects: 369
Study 24620447 — intervention group
Group type: COMPARATOR
Intervention: Dual therapies (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, AML 10/HCTZ 25 mg)
Number of subjects: 369
Study 24620447 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug therapy
Number of subjects: 369
Study 24620447 — intervention group
Group type: COMPARATOR
Intervention: Dual therapies
Number of subjects: 369
Study 22503212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 50 mg
Number of subjects: 38
Study 22503212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 75 mg
Number of subjects: 38
Study 22503212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 100 mg
Number of subjects: 38
Study 19040270 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional eaters
Number of subjects: 21
Study 19040270 — intervention group
Group type: COMPARATOR
Intervention: Nonemotional eaters
Number of subjects: 21
Study 17323180 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 984
Study 17323180 — intervention group
Group type: COMPARATOR
Intervention: Daily bisphosphonate (alendronate 10 mg/day or risedronate 5 mg/day)
Number of subjects: 984
Study 15447752 — intervention group
Group type: EXPERIMENTAL
Intervention: scVSC
Number of subjects: 2056
Study 15447752 — intervention group
Group type: COMPARATOR
Intervention: PVSC
Number of subjects: 2056
Study 15447752 — intervention group
Group type: COMPARATOR
Intervention: AC
Number of subjects: 2056
Study 11498460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin (S‐N)
Number of subjects: 153
Study 11498460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin plus Antioxidants (S‐N+A)
Number of subjects: 153
Study 11498460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 9663484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined neutralization of TNFalpha and interleukin-1 (IL-1)
Number of subjects: 0
Study 9663484 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha monoclonal antibody treatment
Number of subjects: 0
Study 9663484 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNFalpha monoclonal antibody treatment with methotrexate
Number of subjects: 0
Study 9663484 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0